concurrent chemotherapy-Shandong Cancer Hospital and Institute

concurrent chemotherapy-Shandong Cancer Hospital and Institute refers to the specific chemotherapy regimen used in conjunction with radiotherapy in clinical trials led by the Shandong Cancer Hospital and Institute, particularly the Phase III trial NCT06246344 for locally advanced rectal cancer. In this protocol, the concurrent chemotherapy agent is capecitabine, an oral fluoropyrimidine carbamate prodrug. Capecitabine is converted to 5-fluorouracil (5-FU) in a three-step enzymatic process, with the final conversion occurring primarily in tumor tissues via thymidine phosphorylase. The active metabolite, 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), binds to and inhibits thymidylate synthase, thereby blocking the synthesis of thymidine triphosphate and inhibiting DNA synthesis. This treatment is intended to enhance the efficacy of neoadjuvant radiotherapy and provide early systemic control of the disease.

Other names

Concurrent chemotherapy